Abstract
Hereditary hemorrhagic telangiectasia is an inherited disease related to an alteration in angiogenesis, manifesting as cutaneous telangiectasias and epistaxis. As complications, it presents vascular malformations in organs such as the lung, liver, digestive tract, and brain. Currently, diagnosis can be made using the Curaçao criteria or by identifying the affected gene. In recent years, there has been an advance in the understanding of the pathophysiology of the disease, which has allowed the use of new therapeutic strategies to improve the quality of life of patients. This article reviews some of the main and most current evidence on the pathophysiology, clinical manifestations, diagnostic approach, screening for complications, and therapeutic options, both pharmacological and surgical.
Reference75 articles.
1. Federación Española de Enfermedades Raras
https://enfermedades-raras.org/index.php/enfermedades-raras
2. Epistaxis as an indication of impaired nutrition and of degeneration of the vascular system;Sutton;Med. Mirror,1864
3. Épistaxis répétées chez un sujet porteur de petits angiomes cutanés et muqueux;Rendu;Bull. Mem. Soc. Med. Hop.,1896
4. Hereditary haemorrhagic telangiectasia: Pathophysiology, diagnosis and treatment
5. Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT)
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献